Published: 2018-09-25

Clinical determinants of thirty-day mortality in a cohort of patients with severe alcoholic hepatitis

R. K. Kollipara, Sree Geetha, K. P. R. Rao


Background: Aim and objectives was to study clinical profile of patients with severe alcoholic hepatitis (SAH) and evaluate clinical factors associated with short term (30-day) mortality.

Methods: This is a prospective study conducted from January 2016 to January 2017 at Liver Care Unit, Osmania General Hospital. This study was approved by ethics committee of the hospital and written informed consent was obtained from all subjects included in the study. Patients with clinical alcoholic hepatitis with serum bilirubin >5mg/dl, aspartate amino transferase (AST)/ alanine amino transferase (ALT) ratio >2 with an AST level >45 but <500U/L, Maddrey’s Discriminant function (MDF) ≥32 were included in the study.

Results: The 30-day mortality of severe AH in the current study was 40%. Alcoholic hepatitis was most common in males between 40-50 years with a median age of 46.9±7.7 (31-60) years. The clinical complications consisted of hepatic encephalopathy (HE) in 40%, hepato renal syndrome (HRS) and renal failure in 18.2% and infections in 40%. HRS, bilirubin, ALT, AST, urea, creatinine, Na+ and all prognostic scores showed significant association with in hospital mortality at 30days on univariate analysis while United Kingdom end liver disease (UKELD) and Child-Turcotte-Pugh (CTP) scores showed most significance on multivariate regression analysis.

Conclusions: The 30-day mortality of severe AH in the current study was 40%. High UKELD, CTP scores and presence of HRS/Renal dysfunction at time of admission are associated with high 30-day mortality. Patients with advanced age, decompensated cirrhosis, coagulopathy, renal injury, malnourished status and low sodium respond poorly to therapy.


Alcoholic hepatitis, Bilirubin, Creatinine, Mortality, Prognosis

Full Text:



Morgan TR. Treatment of alcoholic hepatitis. Semin Liver Dis. 1993;13:384-94.

Cohen SM, Ahn J. Review article: the diagnosis and management of alcoholic hepatitis. Aliment Pharmacol Ther. 2009 Jul;30(1):3-13.

Nguyen-Khac E, Thevenot T, Piquet M-A, Benferhat S, Goria O, Chatelain D, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1781-9.

EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57:399-420.

Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterol. 1978;75(2):193-9.

Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1-85.

Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2002;2:2.

Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353-8.

Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol. 2005;42:700-6.

Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, et al. Analysis of factors related to mortality in alcoholic hepatitis and the derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005;54:1174-9.

Forrest EH, Morris AJ, Stewart S, Phillips M, Oo YH, Fisher NC, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut. 2007;56:1743-6.

Dominguez M, Rincon D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al. A New scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 2008;103:2747-56.

Barber K, Pioli S, Blackwell J. Development of a UK score for patients with end-stage liver disease. Hepatology. 2007;46:510A.

Vaa BE, Asrani SK, Dunn W, Kamath PS, Shah VH. Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis. Mayo Clin Proc. 2011;86(1):37-42.

Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Dharancy S, et al. The Lille model: a new tool for thepapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45:1348-54.

O Shea RS, Dasarathy S, McCullough AJ. Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology. 2010;51:307-28.

Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.

Higuera-de la Tijera F, Servín-Caamaño AI, Pérez-Torres E, Salas-Gordillo F, Abdo-Francis JM, Pérez-Hernández JL, et al. Main clinical factors influencing early mortality in a cohort of patients with severe alcoholic hepatitis, and evaluation trough ROC curves of different prognostic scoring systems. Revista Médica Del Hospital General De México. 2014;77(4):160-6.

Potts JR, Goubet S, Heneghan MA, Verma S. Determinants of long-term outcome in severe alcoholic hepatitis. Aliment Pharmacol Ther. 2013;38(6):584-95.

Mendenhall CL, Tosch T, Weesner RE, Garcia-Pont P, Goldberg SJ, Kiernan T, et al. VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein-calorie malnutrition. Am J Clin Nutr. 1986;43:213-8.